A 12-gene immune signature predicts prognosis and identifies KRT6B as a therapeutic target in lung adenocarcinoma - PubMed
7 hours ago
- #KRT6B
- #prognostic model
- #lung adenocarcinoma
- A 12-gene immune signature predicts prognosis in lung adenocarcinoma (LUAD).
- The signature identifies KRT6B as a potential therapeutic target.
- The model was validated using TCGA and three GEO cohorts (GSE3141, GSE30219, GSE50081).
- High-risk patients showed worse overall survival compared to low-risk patients.
- Time-dependent ROC analysis confirmed the model's accuracy for 1-, 2-, and 3-year survival.
- A nomogram incorporating risk score and clinical indicators improved prognostic performance.
- PPI network analysis identified KRT6B as a core hub gene.
- Experimental validation confirmed KRT6B overexpression and its tumor-promoting role in LUAD.